REFERENCES
- Goto E, Yago Y, Matsumoto Y, Tubota K. Impaired functional visual acuity of dry eye patients. Am J Opthal 2002; 133(2)181–186
- Cohen E J. Corneal and external disease in the new millennium. Arch Opthal 2000; 118(7)979–981
- Ram J, Sharma A, Pandav S S, Gupta A, Bambery P. Cataract surgery in patients with dry eyes. J Cataract & Refr Surg 1998; 24(8)1119–1124, [CSA]
- Nelson J D. A clinician looks at the tearfilm. Adv Exp Med & Biol 1998; 438: 1–9, [CSA]
- Moss S E, Klein R, Klein B EK. Prevalence of and risk factors for dry eye syndrome. Arch Ophthal 2000; 118(9)1264–1268, [INFOTRIEVE], [CSA]
- Shimmura S, Shimzaki J, Tsubota K. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea 1999; 18(4)408–411, [INFOTRIEVE], [CSA], [CROSSREF]
- Brewitt H, Sistani F. Dry eye disease: The scale of the problem. Surv Ophthalmol 2001; 45(suppl 2)S199–S202, [INFOTRIEVE], [CSA], [CROSSREF]
- Begley C G, Caffery B, Nichols K, Mitchell Gl, Chalmers R. Results of a dry eye questionnaire from optometric practices in North America. Adv Exp Med & Bio 2002; 506: 1009–1016, [CSA]
- Calogne M. The treatment of dry eye. Surv Opthal 2001; 45(suppl 2)S227–S239, [CSA]
- Pray W S. Self-treatment for minor eye conditions. US Pharmacist 2001; 26(12), [CSA]
- Pflugfelder S C, Solomon S, Stern M E. The diagnosis and management of dry eye: A 25-year review. Cornea 2000; 19(5)644–649, [INFOTRIEVE], [CSA], [CROSSREF]
- Hirsch J D. Considerations in the pharmacoeconomics of dry eye. Manag Care. 2003; 12(12 Suppl)33–38, [INFOTRIEVE], [CSA]
- Dalzell M D. Dry eye: Prevalence, utilization, and economic implications. Manag Care. 2003; 12(12 Suppl)9–13, [INFOTRIEVE], [CSA]
- British National Formulary. 2004, http://www.bnf.org
- Dictionnaire Vidal, Paris 2004, http://www.vidal.fr
- 2004, http://www.rote-liste.de Rote Liste
- Giofil Banca Dati Sanitaria Farmaceutica. 2004, www.giofil.it
- 2004, http://vademecum.medicom.es Vademécum Internacional
- 2004, http://www.lfn.se Läkemedelsförmånsnämnden
- McCarty C A, Bansal A K, Livingston P M, Stanislavsky Y L, Taylor H R. The epidemiology of dry eye in Melbourne, Australia. Ophthal 1998; 105(6)1114–1119, [CSA]
- Balaram M, Schaumberg D A, Dana M R. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 2001; 131: 30–36, [INFOTRIEVE], [CSA], [CROSSREF]
- Tai M., Cosar C B, Cohen E J, Rapnano C J, Laibson P R. The clinical efficacy of silicone punctal plug therapy. Cornea 2002; 21: 135–139, [INFOTRIEVE], [CSA], [CROSSREF]
- Shiell A. Cost of illness studies: No aid to decision making?. Health Policy. 1987; 8: 317–323, [CSA], [CROSSREF]
- Nichols J J, Begley C G, Caffrey B, Jones L A. Symptoms of ocular irritation in patients diagnosed with dry eye. Optom Vis Sci 1999; 76(12)838–844, [INFOTRIEVE], [CSA]
- Schaumberg D A, Sullivan D A, Dana M R. Epidemiology of dry eye syndrome. Adv Exp Med & Biol 2002; 506(Pt B)989–998, [CSA]
- Schein O D, Munuz B, Tielsch J M, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthal. 1997; 124(6)723–728, [INFOTRIEVE], [CSA]
- Lemp M A. Epidemiology and classification of dry eye. Adv Exp Med & Bio 1998; 438: 791–803, [CSA]
- Doughty M J, Fonn D, Richter D, Simpson T, Caffery B, Gordon K. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci 1997; 74(8)624–631, [INFOTRIEVE], [CSA]
- Yazdani C, McLaughlin T, Smeeding J E, Walt J. Prevalence of treated dry eye disease in a managed care population. Clin Ther 2001; 23(10)1672–1682, [INFOTRIEVE], [CSA], [CROSSREF]
- Schmut O, Huber H, Mullner K, Haller E M, Faulborn J. Investigations on the increase of the dry eye syndrome in the years 1960–1994. Spektrum der Augenheilkunde 1995; 9(2)90–91, [CSA]
- Stevens A, Raftery J. Introduction. Health Care Needs Assessment. The Epidemiologically Based Needs Assessment Reviews, A. Stevens, J. Raftery. Radcliffe Medical Press, Oxford. Vol. 1: 11–30
- Das Gupta R, Guest J F. The annual cost of bipolar disorder to UK society. Br J Psych. 2002; 180: 227–233, [CSA], [CROSSREF]
- Guest J F, Cookson R F. Cost of schizophrenia to UK society: An incidence-based cost of illness model for the first five years following diagnosis. PharmacoEconomics 1999; 15(6)597–610, [INFOTRIEVE], [CSA], [CROSSREF]
- Guest J F. The annual cost of chronic obstructive pulmonary disease to the UK's National Health Service. Dis Manag Health Outcomes 1999; 5(2)93–100, [CSA], [CROSSREF]
- Plumb J M, Guest J F. Annual cost of erectile dysfunction to UK society. PharmacoEconomics 1999; 16(6)699–709, [INFOTRIEVE], [CSA], [CROSSREF]
- National Institute for Clinical Excellence, http://www.nice.org.uk/CG012NICEguideline Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care, Clinical Guideline 12 February 2004